Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors.

Psoriasiform eruptions are a classical adverse skin reaction of tumour necrosis factor (TNF)-α inhibitors. The aim of this study was to identify the association between the severity or pattern of psoriasiform reactions and the underlying disease. A retrospective study was conducted between January 2012 and May 2015. Adult patients who developed psoriasiform eruptions whilst being treated with TNFα inhibitors were included. For each patient, 3 independent blinded dermatologists graded twice the severity of the lesions according to 6 clinical psoriasiform eruption types. Inter- and intra-individual kappa tests were performed to evaluate the robustness of the scoring system. The association between severity score levels or the pattern of reactions and the underlying disease was assessed. The severity scoring system showed good inter- and intra-observer reproducibility. Women patients treated with TNFα inhibitors for inflammatory bowel diseases showed a higher risk of developing severe reactions with scalp and skin-fold involvement.

[1]  J. Gisbert,et al.  Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study , 2016, Inflammatory bowel diseases.

[2]  A. Steiner,et al.  Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. , 2016, Acta dermato-venereologica.

[3]  L. Peyrin-Biroulet,et al.  Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience , 2015, The American Journal of Gastroenterology.

[4]  Leyla J. Ghazi,et al.  Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease , 2015, Digestive Diseases and Sciences.

[5]  L. Guidi,et al.  Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[6]  S. Brand,et al.  Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment , 2013, Gut.

[7]  J. Korzenik,et al.  Psoriasis associated with anti‐tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature , 2011, Alimentary pharmacology & therapeutics.

[8]  C. Libert,et al.  The X chromosome in immune functions: when a chromosome makes the difference , 2010, Nature Reviews Immunology.

[9]  S. Lepreux,et al.  Cytokine imbalance with increased production of interferon‐α in psoriasiform eruptions associated with antitumour necrosis factor‐α treatments , 2009, The British journal of dermatology.

[10]  P. Barachini,et al.  Psoriasis Induced by Infliximab in a Patient Suffering from Crohn's Disease , 2009, International journal of immunopathology and pharmacology.

[11]  G. Fiorino,et al.  Review article: anti TNF‐α induced psoriasis in patients with inflammatory bowel disease , 2009, Alimentary pharmacology & therapeutics.

[12]  A. Gottlieb,et al.  Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases , 2009, The Journal of dermatological treatment.

[13]  J. S. Henning,et al.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. , 2008, Arthritis and rheumatism.

[14]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[15]  M. Lebwohl,et al.  Potential complications associated with the use of biologic agents for psoriasis. , 2007, Dermatologic clinics.

[16]  M. Martinka,et al.  Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. , 2007, Archives of dermatology.

[17]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[18]  P. Jüni,et al.  Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. , 2005, Rheumatology.

[19]  E. Fonseca,et al.  Psoriasiform Eruption Induced by Infliximab , 2004, The Annals of pharmacotherapy.

[20]  P. V. van Riel,et al.  Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[21]  G. Kollias,et al.  Tumor necrosis factor biology in experimental and clinical arthritis , 2003, Current opinion in rheumatology.

[22]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[23]  D V Cicchetti,et al.  Assessing Inter-Rater Reliability for Rating Scales: Resolving some Basic Issues , 1976, British Journal of Psychiatry.

[24]  V. Pascual,et al.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.